SCHEMBL5215296

SCHEMBL5215296

CC(=O)c1cnc(N)o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838907 0.80
SCHEMBL7923464 0.78 FAAH (0.43)
SCHEMBL19303879 0.78 FBP1 (0.35)
SCHEMBL20970380 0.78 CPB2 (0.36)
SCHEMBL12159793 0.76
SCHEMBL5215292 0.75 FAAH (0.47)
SCHEMBL12939836 0.74
SCHEMBL16503651 0.74
SCHEMBL1705417 0.74 NLRP3 (0.46)
SCHEMBL5211059 0.71 NPC1 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1653952-A4 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2007-04-04 EP claimed
US-7112599-B2 Oxazole compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2006-09-26 US claimed
EP-1653952-A2 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 EP claimed
WO-2005016267-A2 OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-02-24 WO claimed
US-20050032859-A1 Oxazole compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2005-02-10 US claimed
EP-0138464-B1 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE DERIVATIVES PFIZER INC. (US) 1989-11-15 EP claimed
EP-0138464-A2 2-Amino-5-hydroxy-4-methylpyrimidine derivatives PFIZER INC. (US) 1985-04-24 EP claimed
EP-0116769-A1 Dihydropyridines Pfizer Limited (GB) 1984-08-29 EP claimed
US-20210369716-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS AG (CH) 2021-12-02 US disclosed
US-11053234-B2 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-07-06 US disclosed
US-10596175-B2 Compounds and compositions for the treatment of parasitic diseases NOVARTIS AG (CH) 2020-03-24 US disclosed
EP-3526206-A1 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2019-08-21 EP disclosed
US-20190241554-A1 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-08-08 US disclosed
US-20190000852-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2019-01-03 US disclosed
US-4554276-A ENZYME INHIBITORS, ANTIULCER AGENTS PFIZER INC. (US) 1985-11-19 US disclosed
EP-0138464-A2 2-Amino-5-hydroxy-4-methylpyrimidine derivatives PFIZER INC. (US) 1985-04-24 EP disclosed
EP-0138464-A2 2-Amino-5-hydroxy-4-methylpyrimidine derivatives PFIZER INC. (US) 1985-04-24 EP disclosed
EP-0116769-A1 Dihydropyridines Pfizer Limited (GB) 1984-08-29 EP disclosed
US-4435396-A FROM 2-AMINO-5-ACETYLOXAZOLE PFIZER INC. (US) 1984-03-06 US disclosed
EP-0094191-A1 Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)-thiazoles and process therefor PFIZER INC. (US) 1983-11-16 EP disclosed